Jenrin on ‘Peripherally Selective’ Path to Treat Diabetes
By Marie Powers
Friday, September 13, 2013
Virtual biotech Jenrin Discovery LLC spent its first six years targeting peripherally selective (PS) CB1 receptor antagonists as a safer and more effective approach to treat diabetes and other metabolic disorders.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.